Duke University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 19 Carcinoma, Non-Small-Cell Lung studies with Duke University as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 1 2Phase 2 14No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer PatientsNot yet recruitingNCT07869329Not applicable
• TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingNCT06385262Phase 2
• Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibTerminatedNCT04099836Phase 2Results posted
• A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsCompletedNCT03434418Phase 2Results posted
• Locally Advanced NSCLC Hyperfractionated RTCompletedNCT03128008Phase 2Results posted
• Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung CancerTerminatedNCT02157116Phase 2Results posted
• Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571TerminatedNCT02127372Phase 1/2Results posted
• Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01820754Phase 2Results posted
• Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLCTerminatedNCT00787267Phase 2Results posted
• Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung CancerTerminatedNCT00564876Phase 2Results posted
• Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung CancerTerminatedNCT00545948Phase 2Results posted
• Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung CancerTerminatedNCT00509366Phase 2Results posted
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
• SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung CancerWithdrawnNCT04650490Phase 2
• Onco-primary Care Networking to Support TEAM-based CareActive, not recruitingNCT04258813Not applicable
• Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung CancerCompletedNCT02848872
• Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic MalignanciesCompletedNCT00921739Phase 1
• Feasibility of Exercise With Post-Op Lung Cancer PatientsCompletedNCT00636571Not applicable
• EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung CancerCompletedNCT00041028Phase 2